Cargando…

Low-Dose Prednisone Treatment for IVIG-Resistant Kawasaki Disease with Severe Arthritis and Joint Effusion in Two 3-Year-Old Children

Kawasaki disease (KD) is a global disease in children. The etiology and pathogenesis are unknown. Complications vary among patients. Fever can persist in some after immune globulin (IVIG) administration, termed IVIG-resistant KD. Here, we report two cases of IVIG-resistant KD with severe arthritis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Lingling, Lv, Huimin, Jiang, Shujuan, Qin, Daogang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034992/ https://www.ncbi.nlm.nih.gov/pubmed/33868737 http://dx.doi.org/10.1155/2021/6618346

Ejemplares similares

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge
por: de Magalhães, Cristina Medeiros Ribeiro, et al.
Publicado: (2012)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
por: Dionne, Audrey, et al.
Publicado: (2018)

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease
por: Zhang, Rui Long, et al.
Publicado: (2020)

DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease
por: Portman, Michael A, et al.
Publicado: (2013)

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment
por: Kim, Ju Young, et al.
Publicado: (2014)

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
por: Crayne, Courtney B., et al.
Publicado: (2019)

Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy
por: Soltner, Elise, et al.
Publicado: (2009)

An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children
por: Conte, Cristiano, et al.
Publicado: (2023)

Observation on the clinical effect of high-dose Intravenous Immunoglobulin combined with low-dose prednisone acetate in the treatment of patients with Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2021)

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
por: Wang, Zhouping, et al.
Publicado: (2020)

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment
por: Chen, Zhen, et al.
Publicado: (2023)

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease
por: Yoon, Kyung Lim, et al.
Publicado: (2017)

Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness
por: Niu, Man Man, et al.
Publicado: (2021)

Prednisone and Prednisolone in the Treatment of Rheumatoid Arthritis
por: Montgomery, D. A. D.
Publicado: (1957)

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease
por: Kitoh, Toshiyuki, et al.
Publicado: (2021)

Dose‐dependent inhibition of demyelination and microglia activation by IVIG
por: Winter, Meike, et al.
Publicado: (2016)

Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review
por: Beltrametti, Stefano Paolo, et al.
Publicado: (2016)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease
por: Inoue, Takashi, et al.
Publicado: (2020)

Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort
por: Li, Yujie, et al.
Publicado: (2022)

A 6-Year-Old Boy with COVID-19-Positive Pleural Effusion and Kawasaki-Like Features
por: Yousefzadegan, Sedigheh, et al.
Publicado: (2021)

Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease
por: Li, Sung-Chou, et al.
Publicado: (2016)

The “Intermediate” CD14 + CD16 + monocyte subpopulation plays a role in IVIG responsiveness of children with Kawasaki disease
por: Kim, Yi Seul, et al.
Publicado: (2021)

PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway
por: Sun, Ye, et al.
Publicado: (2023)

Clinical characteristics and correlation analysis of IVIG resistance in children with kawasaki disease complicated with hip synovitis: case-control study
por: Wang, Jianjie, et al.
Publicado: (2023)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
por: Buttgereit, Frank, et al.
Publicado: (2013)

The risk of hospitalization for respiratory tract infection (RTI) in children who are treated with high-dose IVIG in Kawasaki Disease: a nationwide population-based matched cohort study
por: Lei, Wei-Te, et al.
Publicado: (2018)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

High-density Genotyping of Immune Loci in Kawasaki Disease and IVIG Treatment Response in European-American Case-parent Trio Study
por: Shendre, Aditi, et al.
Publicado: (2014)

The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease
por: Samadli, Sama, et al.
Publicado: (2019)

The Associated of the Risk of IVIG Resistance in Kawasaki Disease with ZNF112 Gene and ZNF180 Gene in a Southern Chinese Population
por: Lu, Zhaojin, et al.
Publicado: (2022)

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
por: Li, Zheng, et al.
Publicado: (2023)

The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity
por: Cimmino, Marco A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v6e6kjjanabmt6tip9sdd1nmug